Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New Treatment Options for MASLD Patients with Type 2 Diabetes.

Life (Basel, Switzerland)·2026
Same author

Sex Hormones and the Liver: Implications for Disease Progression and Hormonal Therapy.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

An update on novel investigational agents for the treatment of primary biliary cholangitis.

Expert opinion on investigational drugs·2025
Same author

Prognostic value of liver stiffness measurement vs. biochemical response in primary biliary cholangitis.

Journal of hepatology·2025
Same author

Reviewing novel findings and advances in diagnoses and treatment of primary biliary cholangitis.

Expert review of gastroenterology & hepatology·2025
Same author

Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world.

JHEP reports : innovation in hepatology·2025

Related Experiment Videos

Liver diseases in the elderly: an update.

Annarosa Floreani1

  • 1Department of Surgical and Gastroenterological Sciences, University of Padova, Padova, Italy. annarosa.floreani@unipd.it

Digestive Diseases (Basel, Switzerland)
|May 1, 2007
PubMed
Summary

Liver disease management in the elderly requires special attention, as conditions like non-alcoholic fatty liver disease and hepatitis C present unique challenges. Treatment approaches, including antiviral therapy and transplantation, need careful consideration for older patients.

Related Experiment Videos

Area of Science:

  • Hepatology
  • Geriatric Medicine
  • Internal Medicine

Background:

  • Liver diseases present unique challenges in the elderly, differing from younger adults in clinical course and management.
  • Recent advancements in liver disease knowledge and emerging conditions like non-alcoholic steatohepatitis complicate clinical practice.
  • Specific liver conditions in older adults, including non-alcoholic fatty liver disease, chronic hepatitis C, alcoholic liver disease, and hepatocellular carcinoma, warrant re-evaluation.

Purpose of the Study:

  • To highlight the distinct aspects of liver disease management in the elderly.
  • To review key liver diseases and therapeutic strategies relevant to aging populations.
  • To emphasize the need for tailored approaches in geriatric hepatology.

Main Methods:

  • Literature review and synthesis of current research on liver diseases in the elderly.
  • Analysis of clinical course and management strategies for prevalent liver conditions in older adults.
  • Discussion of novel therapeutic options and their applicability in elderly patients.

Main Results:

  • While no liver diseases are exclusive to advanced age, their presentation and progression can vary significantly in older individuals.
  • Emerging conditions such as non-alcoholic steatohepatitis (NASH) and novel treatments require careful assimilation into clinical practice for the elderly.
  • Specific conditions like NAFLD, chronic hepatitis C, alcoholic liver disease, and hepatocellular carcinoma necessitate focused attention in geriatric populations.

Conclusions:

  • Management of liver diseases in the elderly requires a nuanced approach, considering age-related physiological changes.
  • Antiviral therapies and liver transplantation may be viable options for selected elderly patients, demanding careful case-by-case evaluation.
  • Continued research and updated clinical guidelines are essential for optimizing liver disease care in aging populations.